Phase 1Not yet recruitingAge-related condition

Safety Study of Intravenous MiraMSC in Older Adults With Mild to Moderate Frailty Syndrome

A Phase I, Open-Label Study to Evaluate the Safety and Tolerability of MiraMSC Administered Intravenously in Elderly Subjects With Mild to Moderate Frailty Syndrome

Sponsor
Miracle Biomedical Co., Ltd. (Industry)
Enrollment
12 planned
Conditions
Frailty
Interventions
MiraMSC-FS-001
Ages
adults, older adults
Registry
NCT07705464

Full record on ClinicalTrials.gov

From the registry

The purpose of this Phase I, open-label study is to evaluate the safety and tolerability of intravenous MiraMSC-FS-001 in older adults with mild to moderate frailty syndrome. MiraMSC-FS-001 is an investigational product consisting of allogeneic umbilical cord-derived mesenchymal stem cells (UCMSCs). Eligible participants will receive intravenous administration of MiraMSC-FS-001.

Primary outcomes

  • Maximum Feasible Dose (MFD) of MiraMSC-FS-001
  • Incidence of dose-limiting toxicities (DLTs) and treatment-emergent adverse events (TEAEs)

History

  1. Primary completion expected

  2. Expected to start

  3. Registered